单克隆抗体的组合糖基工程及其在癌症治疗中的应用:叙述性综述
Siyuan Wang1, Huairu Tian1, Peilin Tian1
1Suzhou Institute for Drug Control, Suzhou, China.
Translational cancer research
|March 14, 2024
概括
单克隆抗体 (mAbs) 的糖基工程对于优化其治疗疗效和安全至关重要. 本综述详细介绍了用于增强抗体依赖细胞中介细胞毒性 (ADCC) 和保质期的糖基工程策略,特别是在癌症治疗中.
科学领域:
- 生物制药工程 生物制药工程
- 葡萄糖科学 (Glycoscience) 是一种科学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 单克隆抗体 (mAbs) 在免疫疗法中具有革命性作用,糖化对它们的结构和功能产生重大影响.
- 有效监测和设计mAb糖化是确保整个生命周期的治疗安全性和有效性至关重要的.
研究的目的:
- 为制药行业审查mAb糖基工程的现状.
- 讨论糖基工程mAbs在癌症治疗中的应用.
主要方法:
- 在PubMed/MEDLINE (1970-2023) 的综合文献搜索中,搜索了关于重组mAb糖基工程的研究.
- 总结了关于糖化样和mAb特性的主要发现.
主要成果:
- 糖化样式显著影响抗体依赖的细胞介导细胞毒性 (ADCC),补剂依赖的细胞毒性 (CDC) 和保质期.
- 合理的糖基工程设计解决了新药开发和生物类似制造方面的需求.
- 组合型糖基工程策略在生物制造中提供了优化的糖基化模式.
结论:
- 基因和代谢糖基因工程实现了糖的修饰.
- 了解细胞与环境的相互作用可以实现精确的组合糖基工程.
- 先进的糖基工程方法正在推进生物治疗和生物工程.
相关概念视频
01:31Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K